Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

J&J unit win shuts door on Sandoz generic launch
Pharma
J&J unit win shuts door on Sandoz generic launch
Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.   10 September 2026
Abbott clinches 18-country PI in glucose monitoring feud
MedTech
Abbott clinches 18-country PI in glucose monitoring feud
The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.   9 September 2026
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
Pharma
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.   7 September 2026
Regulation & Industry
G 1/25: EPO settles controversial patent description question
Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.   4 September 2026
MedTech
Sun Pharma import ban back in force after Squires intervention
A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.   3 September 2026
Careers
‘Busiest’ US district patent judge swaps bench for private practice
One of the country's most prominent patent judges has joined A&O Shearman after nearly eight years on the federal bench.   2 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.   25 August 2026
Biotech
10x Genomics dealt major blow in sequencing fight
Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.   20 August 2026
Pharma
SK Biopharmaceuticals settles epilepsy generic dispute
A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.   20 August 2026
Pharma
Vanda revives challenge over braille-free label on generic sleep disorder drug
Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.   19 August 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.